I stumbled upon an abstract published at the end of February 2010 that raised a number of questions about hormone therapy (ADT) and its effect on the immune system. Coming out of the starting gate I assumed that ADT would adversely affect the immune system making us prone to falling victim to all sort of [...]
One of the constant complaints I hear fro men with advanced prostate cancer that has become castrate resistant about Provenge (sipuleucel-T) is that the anticipated increase in overall survival is only 4.1 months and given the cost of $93,000 for the three infusions many men feel that cost does not justify the survival benefit. My [...]
On September 27th Dendreon announced that it has enrolled and started its first patient with metastatic advanced prostate cancer that is castrate resistanr in a European Union based clinical trial of Provenge. Finally, men in the EU can hope that in the near future that Provenge could become available to them. The trial is hoped [...]
We all know that abiraterone acetate (Zytiga) plus prednisone provides a survival advantage for men with castrate resistant advanced prostate cancer (mCRPC) who have had prior treatment with a taxane based chemotherapy. New information has shown that abiraterone acetate offers a somewhat longer overall survival benefit than the data originally presented when the trial halted [...]
The summer is coming to a close and I am back, ready to again take on the world. I had the fantastic opportunity of spending almost two weeks in Alaska, a land that is so different from the lower 48. I have to say that I have a new found respect for those individuals who [...]